The Oral Delivery of Water‐Soluble Phenol TS‐13 Ameliorates Granuloma Formation in an In Vivo Model of Tuberculous Granulomatous Inflammation
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Abstract
The redox‐sensitive signaling system Keap1/Nrf2/ARE is a premier protective mechanism against oxidative stress that plays a key role in the pathogenesis and development of various diseases, including tuberculous granulomatous inflammation. We have previously reported that novel water‐soluble phenolic antioxidant TS‐13 (sodium 3‐(4 ′‐methoxyphenyl)propyl thiosulfonate) induces Keap1/Nrf2/ARE and attenuates inflammation. The aim of this study is the examination of the effect of TS‐13 on tuberculous granulomatous inflammation. BALB/c mice were administered TS‐13 (100 mg kg-1 day-1) through their drinking water starting immediately after Bacillus Calmette‐Guérin (BCG) intravenous injection. Histological changes, production of reactive oxygen species (ROS) (activity of free‐radical oxidation processes), and mRNA expression of Nrf2‐driven, NF‐κB‐, AP‐1‐, and autophagy‐dependent signal pathway genes in the liver and peritoneal exudate were evaluated 30 days later. After the 30th day of infection, the activity of the Keap1/Nrf2/ARE system was decreased and its effector genes entailed increasing ROS production in the liver. Therapeutic intervention with TS‐13 is aimed at activating the Keap1/Nrf2/ARE system that leads to an increase in Nrf2 and Nrf2‐mediated gene expression and a decrease in NF‐κB expression. Changes in these pathways resulted in a decline of ROS production and a decrease in the number and the size of granulomas. In total, the results indicate that the Keap1/Nrf2/ARE system can be an effective pharmacological target in host‐adjunctive treatment of tuberculosis.Keywords
This publication has 27 references indexed in Scilit:
- Activation of Nrf2 signaling by oltipraz inhibits death of human macrophages with mycobacterium tuberculosis infectionBiochemical and Biophysical Research Communications, 2020
- Novel Treatments against Mycobacterium tuberculosis Based on Drug RepurposingAntibiotics, 2020
- Antimycobacterial Effects of Everolimus in a Human Granuloma ModelJournal of Clinical Medicine, 2020
- Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune ModulationAntibiotics, 2020
- Resolvin D1 (RvD1) and maresin 1 (Mar1) contribute to human macrophage control of M. tuberculosis infection while resolving inflammationInternational Immunopharmacology, 2019
- Mycobacterium tuberculosis induces connective tissue growth factor expression through the TLR2‐JNK‐AP‐1 pathway in human lung fibroblastsThe FASEB Journal, 2019
- Pasakbumin A controls the growth of Mycobacterium tuberculosis by enhancing the autophagy and production of antibacterial mediators in mouse macrophagesPLOS ONE, 2019
- Host-targeted therapy for tuberculosisIndian Journal of Medical Research, 2018
- Expression of nuclear factor, erythroid 2-like 2-mediated genes differentiates tuberculosisTuberculosis, 2016
- Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a reviewSeminars in Immunopathology, 2015